Drugs "refund" scheme proposed for England and Wales.
作者信息
Mayor Susan
出版信息
BMJ. 2007 Jun 9;334(7605):1181. doi: 10.1136/bmj.39238.353657.DB.
Abstract
摘要
相似文献
1
Drugs "refund" scheme proposed for England and Wales.
BMJ. 2007 Jun 9;334(7605):1181. doi: 10.1136/bmj.39238.353657.DB.
2
Bortezomib in multiple myeloma.
N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8. doi: 10.1056/NEJMc051943.
3
Satisfaction guaranteed--"payment by results" for biologic agents.
N Engl J Med. 2007 Oct 18;357(16):1575-7. doi: 10.1056/NEJMp078204.
4
Bortezomib for myeloma -- much ado about something.
N Engl J Med. 2005 Jun 16;352(24):2546-8. doi: 10.1056/NEJMe058059.
5
Are the Scots getting a better deal on prescribed drugs than the English?
BMJ. 2006 Oct 28;333(7574):875. doi: 10.1136/bmj.333.7574.875.
6
Bortezomib.
Nat Rev Drug Discov. 2003 Aug;2(8):611-2. doi: 10.1038/nrd1159.
7
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Eur J Haematol. 2010 Dec;85(6):484-91. doi: 10.1111/j.1600-0609.2010.01526.x.
8
[Inappropriate commercial presentation of selected drugs and associated overcost].
Farm Hosp. 2006 May-Jun;30(3):195-6. doi: 10.1016/s1130-6343(06)73972-1.
9
Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
Manag Care Interface. 2004 Sep;17(9):52-61.
10
Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Leuk Res. 2007 May;31(5):721-3. doi: 10.1016/j.leukres.2006.06.019. Epub 2006 Aug 4.
引用本文的文献
1
How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements.
MDM Policy Pract. 2021 Feb 9;6(1):2381468321990404. doi: 10.1177/2381468321990404. eCollection 2021 Jan-Jun.
2
A new model for reimbursing genome-based cancer care.
Oncologist. 2014 Jan;19(1):1-4. doi: 10.1634/theoncologist.2013-0392. Epub 2013 Dec 5.
Zotero 插件